Zobrazeno 1 - 10
of 17
pro vyhledávání: '"MI Martin Herranz"'
Autor:
A Martínez Pradeda, MT Rabuñal Alvarez, F Busto Fernández, T Calleja Chucla, M Mateos Salvador, E Fernandez Gabriel, A Luaces Rodriguez, P Feijoo Vilanova, S Rotea Salvo, C Fernández Oliveira, MI Martin Herranz
Publikováno v:
Section 4: Clinical pharmacy services.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6043307d1a24462679850659a5b1f170
https://doi.org/10.1136/ejhpharm-2022-eahp.134
https://doi.org/10.1136/ejhpharm-2022-eahp.134
Autor:
A Martínez Pradeda, P Feijoo Vilanova, C Fernández Oliveira, M Garcia Queiruga, B Feal Cortizas, MJ Mauriz Montero, A Luaces Rodriguez, S Rotea, V Gimenez-Arufe, MI Martin Herranz
Publikováno v:
Section 4: Clinical pharmacy services.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::98371ac977e1dcc0ab03f54ebbf20932
https://doi.org/10.1136/ejhpharm-2022-eahp.115
https://doi.org/10.1136/ejhpharm-2022-eahp.115
Publikováno v:
Section 5: Patient Safety and Quality Assurance.
Background Care transitions are critical points regarding medications errors because of the high number of treatment modifications that are carried out. Medication reconciliation (MR) and providing accurate information to the patients about their tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::891513cae9977a3dbba63f89f54f20b8
https://doi.org/10.1136/ejhpharm-2019-eahpconf.577
https://doi.org/10.1136/ejhpharm-2019-eahpconf.577
Autor:
M Lestón Vázquez, N Fernández Bargiela, V Giménez Arufe, MI Martin Herranz, M.J. Mauriz Montero, C Mondelo Garcia
Publikováno v:
Eur J Hosp Pharm
Background The increase in elderly patients with comorbilities who are treated with direct-acting oral anticoagulants (DOACs) makes necessary an individualised pharmacotherapy follow-up during hospitalisation. Purpose Our objective is to describe the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b4d1988e516c922751ec9fbe03ca79a
https://doi.org/10.1136/ejhpharm-2018-eahpconf.106
https://doi.org/10.1136/ejhpharm-2018-eahpconf.106
Autor:
J Balea Filgueiras, MI Martin Herranz, N Fernández Bargiela, C Fernández Olivera, V Giménez Arufe, C Mondelo Garcia
Publikováno v:
Eur J Hosp Pharm
Background Hypercholesterolaemia is a common and growing health problem, above all in developed countries, which can cause serious consequencies in patients who suffer from it. Alirocumab is a monoclonal antibody that blocks a protein called PCSK9 an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59d444adbe945e8036d7c6bb9f57bcc2
https://doi.org/10.1136/ejhpharm-2018-eahpconf.128
https://doi.org/10.1136/ejhpharm-2018-eahpconf.128
Publikováno v:
Pharmacokinetics and pharmacodynamics.
Background Peritonitis is a frequent complication in peritoneal dialysis. Intraperitoneal administration of antibiotics appears to improve the response to intravenous treatment. Purpose To describe a case of intraperitoneal administration of vancomyc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::328f173785a89adae33c085399977e84
https://doi.org/10.1136/ejhpharm-2017-000640.429
https://doi.org/10.1136/ejhpharm-2017-000640.429
Autor:
V Giménez Arufe, MI Martin Herranz, M Lestón Vázquez, M García Queiruga, C Mondelo Garcia, B Feal Cortizas, N Fernández Bargiela
Publikováno v:
Other hospital pharmacy topics.
Background The availability of biosimilar infliximab (IFX) has been postulated to offer cost savings compared with innovator IFX, which could lead to patients being switched between drugs. Purpose To analyse demographic characteristics and pathologie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f3e212597742960ed931298c26b3d09c
https://doi.org/10.1136/ejhpharm-2017-000640.396
https://doi.org/10.1136/ejhpharm-2017-000640.396
Publikováno v:
Drug information and pharmacotherapy.
Background Vascular anomalies comprise a heterogeneous group of disorders. The presence of D2-40 markers and the Kasabach–Merrit phenomenon (KMP), characterised by thrombocytopenia and consumption coagulopathy, are associated with major morbidity.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::891c1628258b78e674be4674d93eab9d
https://doi.org/10.1136/ejhpharm-2017-000640.254
https://doi.org/10.1136/ejhpharm-2017-000640.254
Publikováno v:
European Journal of Hospital Pharmacy. 23:A33.2-A34
Background Kawasaki disease (KD) is an acute systemic vasculitis of unknown aetiology and a leading cause of acquired heart disease in children in developed countries. Purpose To describe a case of refractory KD in which abciximab was used in order t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b4fd6c97cf6e0430011bcffff8dc117
https://doi.org/10.1136/ejhpharm-2016-000875.76
https://doi.org/10.1136/ejhpharm-2016-000875.76
Publikováno v:
European Journal of Hospital Pharmacy. 23:A87.2-A87
Background Strongiloides stercolaris can produce a life threatening illness in inmunosuppressed hosts. Treatment options are limited to oral formulations and there are few data on alternative therapies. Purpose To describe the preparation of ivermect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f720736baf2026deeceb09426a9b2152
https://doi.org/10.1136/ejhpharm-2016-000875.197
https://doi.org/10.1136/ejhpharm-2016-000875.197